secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001564590-22-037214
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology Q3 net loss narrows to $3.9M; cash of $14.1M supports 12-month runway
--------------------------------------------------------------------------------

- Cash totaled $14.1M as of Sep 30, 2022, up from $10.6M at Dec 31, 2021; proceeds from July IPO added.
- R&D expenses rose to $2.3M (Q3 2022) vs $1.1M (Q3 2021) due to THIO trial startup and clinical prep.
- Net loss improved to $3.9M (Q3 2022) from $5.2M (Q3 2021), primarily due to prior-year loss on convertible notes.
- Presented THIO-101 Phase 2 trial design at ESMO 2022; plans to report safety data in Q4 2022 and efficacy data in 2023.
- Added to Longevity Stock Index; preclinical data for THIO in hepatocellular carcinoma presented at Triple Meeting Symposium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000156459022037214/0001564590-22-037214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000156459022037214/maia-8k_20221109.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-037214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer